Pliaglis is a drug owned by Crescita Therapeutics Inc. It is protected by 5 US drug patents filed from 2013 to 2021. Out of these, 3 drug patents are active and 2 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 14, 2031. Details of Pliaglis's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10603293 | Solid-forming local anesthetic formulations for pain control |
Jan, 2031
(5 years from now) | Active |
| US10751305 | Solid-forming topical formulations for pain control |
Jan, 2031
(5 years from now) | Active |
| US10350180 | Solid-forming local anesthetic formulations for pain control |
Jan, 2031
(5 years from now) | Active |
| US6528086 | Methods and apparatus for drug delivery involving phase changing formulations |
Sep, 2019
(5 years ago) |
Expired
|
| US5919479 | Noninvasive dermal anesthetics |
Jul, 2015
(9 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Pliaglis's patents.
Latest Legal Activities on Pliaglis's Patents
Given below is the list of recent legal activities going on the following patents of Pliaglis.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Feb, 2024 | US10751305 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 02 Oct, 2023 | US10603293 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 16 Jan, 2023 | US10350180 |
| Patent Issue Date Used in PTA Calculation Critical | 25 Aug, 2020 | US10751305 |
| Recordation of Patent Grant Mailed Critical | 25 Aug, 2020 | US10751305 |
| Email Notification Critical | 07 Aug, 2020 | US10751305 |
| Issue Notification Mailed Critical | 05 Aug, 2020 | US10751305 |
| Dispatch to FDC | 22 Jul, 2020 | US10751305 |
| Application Is Considered Ready for Issue Critical | 20 Jul, 2020 | US10751305 |
| Issue Fee Payment Received Critical | 15 Jul, 2020 | US10751305 |
US patents provide insights into the exclusivity only within the United States, but Pliaglis is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Pliaglis's family patents as well as insights into ongoing legal events on those patents.
Pliaglis's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Pliaglis's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 14, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Pliaglis Generics:
There are no approved generic versions for Pliaglis as of now.
Alternative Brands for Pliaglis
There are several other brand drugs using the same active ingredient (Lidocaine; Tetracaine) as Pliaglis. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Galen Specialty |
|
About Pliaglis
Pliaglis is a drug owned by Crescita Therapeutics Inc. Pliaglis uses Lidocaine; Tetracaine as an active ingredient. Pliaglis was launched by Crescita Therap in 2006.
Approval Date:
Pliaglis was approved by FDA for market use on 29 June, 2006.
Active Ingredient:
Pliaglis uses Lidocaine; Tetracaine as the active ingredient. Check out other Drugs and Companies using Lidocaine; Tetracaine ingredient
Dosage:
Pliaglis is available in cream form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 7%;7% | CREAM | Discontinued | TOPICAL |